PCSA News and Press, Processa Pharmaceuticals Inc. From 04/25/24

2024-04-25 08:20:16 ET Barfresh Food Group, Inc. (BRFH) Q4 2023 Earnings Call Transcript POET: 2024 Could Be The Year For The Tide To Turn Processa Pharmaceuticals prices discounted stock and warrants offering to raise $7M Seeking Alpha’s Quant Rating on B...

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, participated at this year’s annual American Association for Canc...

NGC-Cap demonstrated greater 5-FU exposure than monotherapy capecitabine at a significantly lower dose with a favorable clinical safety profile NGC-Cap holds potential for improved efficacy in more patients due to an increase in distribution of 5-FU to cancer cells Phase 1b study ...

A look at the top 10 most actives in the United States Marin Software Incorporated (MRIN) rose 126.3% to $0.6497 on volume of 228,672,822 shares PROSHARES TRUST (SQQQ) rose 2.7% to $10.9 on volume of 177,760,238 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.9% to $3.43 ...

Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced that its CEO George Ng will present a corporate update at the ...

Processa (NASDAQ: PCSA) is a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer. The company today announced that it will have two posters at the American Association for ...

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety...

Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, today announced that its CEO George Ng will present a corporate update at the 2024 BIO CEO &...

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety ...

Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, will be represented at this month’s Winter Wrap-Up MicroCap Rode...